Patterns of Medication Initiation in Newly Diagnosed Diabetes Mellitus: Quality and Cost Implications
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE Six oral medication classes have been approved by the Food and Drug Administration for the treatment of type 2 diabetes. Although all of these agents effectively lower blood glucose, the evidence supporting their impact on other clinical events is variable. There also are substantial cost differences between agents. We aimed to evaluate temporal trends in the use of specific drugs for the initial management of type 2 diabetes and to estimate the economic consequences of non-recommended care. METHODS We studied a cohort of 254,973 patients, aged 18 to 100 years, who were newly initiated on oral hypoglycemic monotherapy between January 1, 2006, and December 31, 2008, by using prescription claims data from a large pharmacy benefit manager. Linear regression models were used to assess whether medication initiation patterns changed over time. Multivariate logistic regression models were constructed to identify independent predictors of receiving initial therapy with metformin. We then measured the economic consequences of prescribing patterns by drug class for both patients and the insurer. RESULTS Over the course of the study period, the proportion of patients initially treated with metformin increased from 51% to 65%, whereas those receiving sulfonylureas decreased from 26% to 18% (P<.001 for both). There was a significant decline in the use of thiazolidinediones (20.1%-8.3%, P<.001) and an increase in prescriptions for dipeptidyl peptidase-4 inhibitors (0.4%-7.3%, P<.001). Younger patients, women, and patients receiving drug benefits through Medicare were least likely to initiate treatment with metformin. Combined patient and insurer spending for patients who were initiated on alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, or dipeptidyl peptidase-4 inhibitors was $677 over a 6-month period compared with $116 and $118 for patients initiated on metformin or a sulfonylurea, respectively, a cost difference of approximately $1120 annually per patient. CONCLUSION Approximately 35% of patients initiating an oral hypoglycemic drug did not receive recommended initial therapy with metformin. These practice patterns also have substantial implications for health care spending.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“gesting possible adverse cardiovascular effects in May 2007.(7) Figure 2 Temporal trends in medication ini”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Projection of Diabetes Burden Through 2050
Boyle, J. P., Honeycutt, A. A., Narayan, K. M. V., Hoerger, T. J., Geiss, L. S., Chen, H., & Thompson, T. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1936 · Cited by 1,004
Cited by
A review of the efficacy and safety of oral antidiabetic drugs
Stein, S. A., Lamos, E. M., & Davis, S. N. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752813 · Cited by 305
Ji, L., Hu, D., Pan, C., Weng, J., Huo, Y., Ma, C., Mu, Y., Hao, C., Ji, Q., Ran, X., et al. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.02.035 · Cited by 254
Nathan, D. M., Buse, J. B., Kahn, S. E., Krause-Steinrauf, H., Larkin, M. E., Staten, M., Wexler, D., Lachin, J. M., & the GRADE Study Research Group (2013) · Diabetes Care · doi:10.2337/dc13-0356 · Cited by 254
Montvida, O., Shaw, J., Atherton, J. J., Stringer, F., & Paul, S. K. (2018) · Diabetes Care · doi:10.2337/dc17-1414 · Cited by 250
“(8) reported an increasing proportional share of MET and decreasing prescriptions for TZD between 2006 and 2008.”
BackgroundShi, Q., Liu, S., Fonseca, V. A., Thethi, T. K., & Shi, L. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024954 · Cited by 144
Metadata
- Authors
- Desai, N. R., Shrank, W. H., Fischer, M. A., Avorn, J., Liberman, J. N., Schneeweiss, S., Pakes, J., Brennan, T. A., & Choudhry, N. K.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 125
- Issue
- 3
- Pages
- 302.e1-302.e7
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W2039741453
- Cited by
- 149
- References
- 4
- FWCI
- 11.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.